SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?


To: Icebrg who wrote (1596)1/4/2007 9:35:37 AM
From: Icebrg  Read Replies (1) | Respond to of 2240
 
Newsweek publishes a story about the EGFRvIII therapy for brain cancer

December 11, 2006
Dr. Samuel Hassenbusch is both a neuroscientist and a brain cancer patient who has entered himself into a clinical trial with the M.D. Anderson Cancer Center to receive the EGFRvIII tumor vaccine for glioblastoma now being developed by Celldex, with encouraging early success. Read the story at: msnbc.msn.com